ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
5.51
-0.39 (-6.69%)
Real-time:   2:06PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.46 - 6.00
52 week 1.51 - 8.04
Open 5.94
Vol / Avg. 2.31M/3.08M
Mkt cap 486.91M
P/E     -
Div/yield     -
EPS -1.63
Shares 89.35M
Beta 2.45
Inst. own 77%
Aug 10, 2017
ImmunoGen Inc at Canaccord Genuity Growth Conference - 10:00AM EDT - Add to calendar
Jul 28, 2017
Q2 2017 ImmunoGen Inc Earnings Call - 8:00AM EDT - Add to calendar
Jul 28, 2017
Q2 2017 ImmunoGen Inc Earnings Release - 6:30AM EDT - Add to calendar
Jun 13, 2017
ImmunoGen Inc Annual Shareholders Meeting
Jun 8, 2017
ImmunoGen Inc at Jefferies Healthcare Conference
May 19, 2017
ImmunoGen Inc to Discuss New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer Conference Call - Webcast
May 5, 2017
Q1 2017 ImmunoGen Inc Earnings Release
May 5, 2017
Q1 2017 ImmunoGen Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -60.86% -
Operating margin -45.24% -
EBITD margin - -
Return on average assets -38.42% -
Return on average equity - -
Employees 308 -
CDP Score - -

Address

830 WINTER ST
WALTHAM, MA 02451-1477
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Mark J. Enyedy President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
David B. Johnston PhD Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Age: 61
Bio & Compensation  - Reuters
Richard J. Gregory Ph.D. Executive Vice President - Research, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Distinguished Research Fellow
Age: 65
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Peter J. Williams Vice President - Business Development
Age: 62
Bio & Compensation  - Reuters
Mark A. Goldberg M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Dean Jonathan Mitchell Independent Director
Age: 61
Bio & Compensation  - Reuters